Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema
Click Here to Manage Email Alerts
Eluminex Biosciences has dosed the first patient in the phase 1b LOTUS trial, which will evaluate three dose levels of the trispecific fusion antibody EB-105 in patients with diabetic macular edema.
“It is our hope that EB-105 will translate into incremental improvements in visual acuity, durability of response and improved drying of the retina,” Ashkan Abbey, MD, director of clinical research at Texas Retinal Associates and the first retinal surgeon to administer the treatment, said in an Eluminex press release.
As Healio recently reported, EB-105 has three major moieties that inhibit VEGF-A, VEGF-B, placental growth factor, angiopoietin-2 and interleukin-6 receptor signaling.
According to the release, the first-in-human, open-label, single intravitreal injection, dose-escalation LOTUS trial will be conducted at four sites in the U.S. and will enroll 12 patients, four per dose level. The study will assess safety, tolerability and pharmacodynamics of EB-105 and determine the two best doses for a repeat injection study planned for 2025.
“EB-105 represents a significant advance in the rapidly emerging science of polyvalent protein engineering,” Charles Semba, MD, Eluminex’s chief medical officer, said in the release. “For patients, it offers the promise of broader coverage of known biologic pathways associated with diabetic retinopathy and potentially better outcomes beyond currently available therapies.”
Read more about
Click Here to Manage Email Alerts